This randomized, double-blind, placebo-controlled phase III trial randomized 154 patients 3:2 to receive either the PARP inhibitor or placebo as maintenance therapy. Patients had to have a germline BRCA1 or BRCA2 mutation and responded to frontline platinum-based chemotherapy for at least 16 weeks. Read more . . .
Olaparib (Lynparza) improved progression-free survival (PFS) compared to placebo in patients with BRCA-mutant metastatic pancreatic cancer, based on data from the phase III POLO trial presented at the 2019 ASCO Annual Meeting.